US equities |
NVDA $237.15 ▲+1.37% SPCX $164.73 ▲+3.63% MU $1,063.56 ▼-1.05% TSLA $378.75 ▲+2.20% MSFT $526.64 ▲+1.76% INTC $116.87 ▼-2.06% SNDK $1,722.25 ▲+0.13% AMD $629.27 ▼-0.73%
FinancialContent

Annovis Bio, Inc. Common Stock (NY:ANVS)

1.164 -0.016 (-1.39%)
Delayed Quote Updated: 10:10 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
Via Investor Brand Network
Topics Intellectual Property
Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members
Via Investor Brand Network
News headline image
Peering Into Annovis Bio's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today? ↗
ANVS stock closed up more than 75% today after Annovis announced encouraging clinical trial results for its Parkinson's drug, buntanetap. 
Via InvestorPlace
News headline image
Peering Into Annovis Bio's Recent Short Interest ↗
 
Via Benzinga
Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
News headline image
Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
Via Investor Brand Network
News headline image
What's Going On With Annovis Shares Today? ↗
Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo. 
Via Benzinga
News headline image
Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today ↗
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory. 
Via Benzinga
Topics Stocks
News headline image
What's Going With Annovis Bio Shares Tuesday? ↗
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson's Disease Rating Scale following treatment with Buntanetap. 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Annovis Announces New Publication in a Peer-Reviewed Journal
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >